ACTIV-2 looks beyond mAb infusions with four new treatment arms
The addition of four new treatment arms spanning diverse mechanisms to NIH’s ACTIV-2 master protocol could give a broader picture of which therapeutic strategies will work in outpatient COVID-19.
The new therapies for the Accelerating COVID-19 Therapeutics and Interventions Vaccines 2 (ACTIV-2) study — an adaptive master protocol evaluating therapies in the mild-to-moderate outpatient setting — include an inhaled immune modulator, an IV and intramuscular mAb and a viral entry inhibitor. ...